TICKERNOMICS Sign up
Last Update: 2024-03-28 02:14:35
Homology Medicines Inc. ( FIXX ) https://www.homologymedicines.com
0.93USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-6.53%
FIXX
SPY
32.74%
-90.20%
FIXX
SPY
92.93%
-96.63%
FIXX
SPY
224.41%
FIXX
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
53.82
7.97
0.40
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.41
19.50
0.74
-148.49
0.00
-0.07
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-8757.34
100.00
-6417.11
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.9112
-395.50
-88.93
0.44
Other Earnings and Cash Flow Stats:
Homology Medicines Inc. ( FIXX ) Net Income TTM ($MM) is -126.28
Homology Medicines Inc. ( FIXX ) Operating Income TTM ($MM) is -125.87
Homology Medicines Inc. ( FIXX ) Owners' Earnings Annual ($MM) is -102.66
Homology Medicines Inc. ( FIXX ) Current Price to Owners' Earnings ratio is -0.53
Homology Medicines Inc. ( FIXX ) EBITDA TTM ($MM) is -124.96
Homology Medicines Inc. ( FIXX ) EBITDA Margin is -6417.11%
Capital Allocation:
Homology Medicines Inc. ( FIXX ) has paid 0.00 dividends per share and bought back -0.61765 million shares in the past 12 months
Homology Medicines Inc. ( FIXX ) has reduced its debt by 1.139 million USD in the last 12 months
Capital Structure:
Homology Medicines Inc. ( FIXX ) Interest-bearing Debt ($MM) as of last quarter is 28
Homology Medicines Inc. ( FIXX ) Annual Working Capital Investments ($MM) are -71
Homology Medicines Inc. ( FIXX ) Book Value ($MM) as of last quarter is 72
Homology Medicines Inc. ( FIXX ) Debt/Capital as of last quarter is 32%
Other Balance Sheet Stats:
Homology Medicines Inc. ( FIXX ) has 39 million in cash on hand as of last quarter
Homology Medicines Inc. ( FIXX ) has 11 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Homology Medicines Inc. ( FIXX ) has 58 common shares outstanding as of last quarter
Homology Medicines Inc. ( FIXX ) has 0 million USD of preferred stock value
Academic Scores:
Homology Medicines Inc. ( FIXX ) Altman Z-Score is -9.83 as of last quarter
Homology Medicines Inc. ( FIXX ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
Homology Medicines Inc. ( FIXX ) largest shareholder is owning shares at 0.00 ($MM) value
Arthur Tzianabos(an insider) Sold 13037 shares of Homology Medicines Inc. ( FIXX ) for the amount of $7431.09 on 2024-01-09
9.18% of Homology Medicines Inc. ( FIXX ) is held by insiders, and 40.35% is held by institutions
Homology Medicines Inc. ( FIXX ) went public on 2018-03-28
Other Homology Medicines Inc. ( FIXX ) financial metrics:
FCF:-103.60
Unlevered Free Cash Flow:-57.71
EPS:-2.27
Operating Margin:-8757.34
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-180.59
Beta:0.44
Buffet's Owners Earnings:-102.66
Price to Owner's Earnings:-0.53
About Homology Medicines Inc. ( FIXX ) :
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. The company's various set of AAVHSCs allows company to precisely target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, blood-brain-barrier, bone marrow, cardiac and skeletal muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; HMI-202 to treat metachromatic leukodystrophy; and HMI-203 for the treatment of mucopolysaccharidosis type II, as well as HMI-104 for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.